Compare HCA Health Inc (HCA) vs Oklo Inc (OKLO) Price & Performance

HCA Healthcare trades at $413.36, up 1.09% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $449.93. The company reported strong Q2 2026 earnings of $7.59 per share, beating estimates, and has shown consistent revenue growth, reaching $75.60 billion in 2025. Recent corporate actions include dividend payments of $0.78 per share, while news highlights executive appointments and ongoing legal investigations.

The stock presents a compelling investment case with attractive valuation multiples like a P/E of 13.86 and robust profitability, but faces risks from legal probes and high debt levels. Upside potential is supported by analyst optimism and solid operational cash flow, though investors should monitor expense pressures and regulatory developments.

OKLO trades at $48.42, up 14.77% in the past 24 hours, with a bullish technical signal and strong analyst consensus. The stock is supported by recent milestones, including the Groves reactor achieving first criticality and reporting its first meaningful revenue of $1.2 million in Q2 2026, though it posted a wider net loss. The company maintains substantial liquidity of approximately $2.5 billion as of March 2026, supporting its aggressive development plans.

The outlook is optimistic due to strong institutional backing and growth potential in the nuclear energy sector, but significant execution risks and persistent losses pose challenges. The consensus price target of $82.69 suggests substantial upside if operational milestones are met, yet the high cash burn and unproven business model warrant caution for investors.